RxDoctor Payments Data

Ludmila Feldman, MD

Neurology · Staten Island, NYNPI 1457326563

Payments from drug & device makers

$10,271in general payments, 2019–2025

Across 548 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$898
  • EMD Serono, Inc.$843
  • Biogen$672
  • TG Therapeutics, Inc.$668
  • AstraZeneca$493
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$10,04798%
  • Education$2242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,271 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$188,553
Medicare patients
520
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5011$294,152
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5020$170,658
UbrelvyUbrogepant50$82,580
VumerityDiroximel Fumarate11$55,374
QuliptaAtogepant19$20,519
Emgality PenGalcanezumab-Gnlm22$19,443
Teriflunomide11$18,093
Ajovy AutoinjectorFremanezumab-Vfrm22$15,472
Aimovig AutoinjectorErenumab-Aooe15$14,052
NeuproRotigotine11$10,288
Gabapentin760$8,544
Eletriptan HbrEletriptan Hydrobromide38$8,488
Pregabalin279$7,998
Lamotrigine ErLamotrigine26$3,947
Levetiracetam187$3,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,932$103,09969 claims
BiogenVumerity$672$55,37411 claims
UCB, Inc.Neupro$185$10,28811 claims
PfizerDilantin$143$3,61611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →